Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.

NCT04291209 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Ototoxic Hearing Loss

Interventions

DRUG: N-Acetyl Cysteine

Sponsor

Sunnybrook Health Sciences Centre

Collaborators

[object Object]
[object Object]